

Summary of Risk Management Plan for Vegzelma™

Active substance:	Bevacizumab
Dosage strength:	25 mg/mL
Pharmaceutical form:	Concentrate for solution for infusion
Version number of RMP summary	1.0
Name of Marketing Authorisation Holder:	iQone Healthcare Switzerland SA
Date:	22 March 2023
Reference RMP	EU RMP version 1.0

Disclaimer:

The Risk Management Plan (RMP) is a comprehensive document submitted as part of the application dossier for market approval of a medicine. The RMP summary contains information on the medicine's safety profile and explains the measures that are taken in order to further investigate and follow the risks as well as to prevent or minimise them.

The RMP summary of Vegzelma™ is a concise document and does not claim to be exhaustive.

As the RMP is an international document, the summary might differ from the “Arzneimittelinformation / Information sur le médicament” approved and published in Switzerland, e.g. by mentioning risks occurring in populations or indications not included in the Swiss authorization.

Please note that the reference document which is valid and relevant for the effective and safe use of Vegzelma™ in Switzerland is the “Arzneimittelinformation/ Information sur le médicament” (see www.swissmedic.ch) approved and authorized by Swissmedic. iQone Healthcare Switzerland SA is fully responsible for the accuracy and correctness of the content of the published summary RMP of Vegzelma™.

Throughout this document, symbols that indicate proprietary names (e.g., ® and ™) are not displayed. The appearance of product names without these symbols does not imply that these names are not protected.

Part VI: Summary of the risk management plan

Summary of risk management plan for Vegzelma (bevacizumab)

This is a summary of the risk management plan (RMP) for Vegzelma. The RMP details important risks of Vegzelma, how these risks can be minimised, and how more information will be obtained about Vegzelma's risks and uncertainties (missing information).

Vegzelma's summary of product characteristics (SmPC) and its package leaflet (PL) give essential information to healthcare professionals (HCPs) and patients on how Vegzelma should be used.

This summary of the RMP for Vegzelma should be read in the context of all this information including the assessment report of the evaluation and its plain-language summary, all of which is a part of the European Public Assessment Report (EPAR).

Important new concerns or changes to the current ones will be included in updates of Vegzelma's RMP.

I. The medicine and what it is used for

Vegzelma is authorised for Metastatic Colorectal Cancer, Metastatic Breast Cancer, Advanced, metastatic or recurrent Non-Small Cell Lung Cancer, Advanced and/or metastatic Renal Cell Cancer, Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer, and Cervical Cancer (see SmPC for the full indications).

It contains bevacizumab as the active substance, and it is given by the intravenous route.

Further information about the evaluation of Vegzelma's benefits can be found in Vegzelma's EPAR, including in its plain-language summary, available on the European Medicines Agency website, under the medicine's webpage:

<https://www.ema.europa.eu/en/medicines/human/EPAR/vegzelma>

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Vegzelma, together with measures to minimise such risks and the proposed studies for learning more about Vegzelma's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g., with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation measures*.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including Periodic Safety Update Report (PSUR) assessment so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

II.A List of important risks and missing information

Important risks of Vegzelma are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Vegzelma. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g., on the long-term use of the medicine).

List of important risks and missing information	
Important identified risks	None
Important potential risks	None
Missing information	None

II.B Summary of important risks

The safety information in the proposed product information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Vegzelma.

II.C.2 Other studies in post-authorisation development plan

There are no other studies in post-authorisation development plan of Vegzelma.